Related Experiment Video

Updated: Mar 3, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

WIP1 phosphatase as pharmacological target in cancer therapy

Soňa Pecháčková1, Kamila Burdová1, Libor Macurek2

  • 1Department of Cancer Cell Biology, Institute of Molecular Genetics of the ASCR, CZ-14220, Prague, Czech Republic.

Journal of Molecular Medicine (Berlin, Germany)
|April 26, 2017
PubMed

Insights

Targeting protein phosphatase 2C delta (WIP1) with novel inhibitors shows promise for cancer treatment. Inhibiting WIP1, a negative regulator of DNA damage response, could suppress tumor growth and enhance therapy sensitivity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The DNA damage response (DDR) pathway is crucial for maintaining genomic stability and preventing cancer.
  • Tumor suppressor p53 integrates DDR, cell cycle checkpoints, and cell fate decisions under genotoxic stress.
  • Mutations in TP53 and DDR genes drive cancer development and affect treatment sensitivity.

Purpose of the Study:

  • To review recent advancements in the development of WIP1 inhibitors.
  • To discuss the therapeutic potential of WIP1 inhibition in cancer treatment.

Main Methods:

  • Literature review of recent studies on WIP1 inhibitors.
  • Analysis of the role of WIP1 in DDR and cancer.

Main Results:

  • Protein phosphatase 2C delta (WIP1) negatively regulates the DDR pathway.
  • Development of selective small-molecule WIP1 inhibitors has been challenging but is advancing.
  • WIP1 inhibition is a potential strategy for cancer therapy.

Conclusions:

  • WIP1 inhibitors represent a promising new avenue for cancer treatment.
  • Targeting WIP1 may enhance the efficacy of existing cancer therapies.
Keywords:
CancerCheckpointDNA damage responseInhibitorPhosphatasep53

More Related Videos

A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors10:17

A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors

Published on: April 29, 2022

2.9K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

845

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Phosphorylation01:02

Phosphorylation

The addition or removal of phosphate groups from proteins is the most common chemical modification that regulates cellular processes. These modifications can affect the structure, activity, stability, and localization of proteins within cells as well as their interactions with other proteins.
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
54.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
18.8K